Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04677179 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Phase 2 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT04677179 is a Phase 2 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 81 participants.
The verdict
NCT04677179, a Phase 2 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
Interventions
- DRUG Placebo
- DRUG LY3471851
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2022-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04677179
The ClinicalTrials.gov registry entry for NCT04677179 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04677179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04677179 about?
NCT04677179 is a clinical study titled "A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)". The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
What is the current status of trial NCT04677179?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2021-03-22. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT04677179?
The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).
Who is sponsoring clinical trial NCT04677179?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.